Lung factor

We are looking for comprehensive solutions 

Our goal is to establish a translational approach to a major clinical problem, where basic research could rapidly applicable to the clinic. Our aims are summarized in the graph below. Our research group has currently established a method for screening potential new drugs for IPF, and tested the first molecules in preclinical models of fibrosis. A Finnish IPF-registry and an IPF -consortium has been established in 2011, where the first patients have given consent to enter the registry.

Copyright: M.Myllärniemi, Lung factor

Now at Lung factor / News

Ethical board approval for the FikSu -study

The ethical board at the Helsinki University Central Hospital has […]

BMC Pulm Med classifies our work as highly accessed

Our systematic review on IPF epidemiology has been ranked as […]

Finnish update on IPF in Duodecim

In the latest issue of Duodecim,  Finnish researchers publish an […]

Follow us on Facebook

Are you interested in our research? Please like us on […]

Archive »